• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Animal & Veterinary

  • Print
  • Share
  • E-mail

NADA 140-921 PrednisTab® - supplemental approval (November 20, 1997)

Approval Date: November 20, 1997

I. GENERAL INFORMATION:

NADA140-921
Sponsor:Lloyd, Incorporated
604 W. Thomas Avenue, P. O. Box A
Shenandoah, Iowa 51601 U.S.A.
Generic Name:prednisolone, USP
Trade Name:PrednisTab®
Marketing Status: 
Effect of Supplement:Provides for a new 20 mg tablet size.

II. INDICATIONS FOR USE

Refer to attached labeling.

III. DOSAGE

A.DOSAGE FORMOral Tablet
B.ROUTE OF ADMINISTRATIONOral
C.RECOMMENDED DOSAGES:2.5 mg per 10 lb. (4.5 kg) body weight per day.
Average total daily oral doses for dogs are as follows:
to 20 lb. (2 to 9 kg) body weight........1.25 to 5 mg
20 to 40 lb. (9 to 18 kg) body weight..........5 to 10 mg
40 to 80 lb. (18 to 36 kg) body weight.......10 to 20 mg
80 to 160 lb. (36 to 73 kg) body weight......20 to 40 mg

IV. EFFECTIVENESS

Refer to the FOI for NADA 140-921 approved November 8, 1991

V. TARGET ANIMAL SAFETY

Refer to the FOI for the original approval for NADA 140-921 approved November 8, 1991.

VI. HUMAN FOOD SAFETY:

Data on human food safety, pertaining to consumption of drug residues in food were not required for approval of this supplemental NADA, since the drug is labeled for use in a non-food animal species (dogs).

VII. AGENCY CONCLUSIONS:

The data submitted in support of this NADA comply with the requirements of Section 512 of the Act and Section 514.111 of the regulations. The data demonstrate that 20 mg PrednisTab® (prednisolone), is safe and effective when used according to the proposed conditions of use.

The drug is restricted to use by or on the order of a licensed veterinarian because a knowledge of veterinary medicine is needed for the accurate diagnosis of conditions for which the drug is indicated and for the determination of the appropriate dose, monitoring of treatment, and adverse reactions.

Under the Center's supplemental approval policy 21 CFR 514.106(b)(2), this is a category II change that did not require reevaluation of the safety or effectiveness data in the parent application.

VIII. LABELING (Attached)

  • Facsimile immediate container (bottle) labels
  • Facsimile package insert labeling
  • Shipping carton labels

Copies of applicable labels may be obtained by writing to the:

Freedom of Information Office
Center for Veterinary Medicine, FDA
7500 Standish Place
Rockville, MD 20855